Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04466150 · ClinicalTrials.gov registry record · Phase 4
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
A Phase 4 study of Relapsing Multiple Sclerosis and Clinically Isolated Syndrome, sponsored by University of California, San Francisco.
- Active
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04466150 is a Phase 4 study of Relapsing Multiple Sclerosis and Clinically Isolated Syndrome that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 30 participants, below the 2,168-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04466150, a Phase 4 study of Relapsing Multiple Sclerosis and Clinically Isolated Syndrome, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Newly diagnosed relapsing multiple sclerosis (MS) and high risk clinically isolated syndrome (CIS) patients will be treated with ocrelizumab at disease onset to see if treatment favorably alters CSF markers of chronic inflammation.
Conditions Studied
Interventions
- DRUG Ocrelizumab
Study Locations (1)
California
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-08-30 |
| Est. Completion | 2027-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04466150
The ClinicalTrials.gov registry entry for NCT04466150 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,168-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (99% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT04466150 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04466150 about?
NCT04466150 is a clinical study titled "Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset". Newly diagnosed relapsing multiple sclerosis (MS) and high risk clinically isolated syndrome (CIS) patients will be treated with ocrelizumab at disease onset to see if treatment favorably alters CSF markers of chronic inflammation.
What is the current status of trial NCT04466150?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2020-08-30. Estimated completion is 2027-07.
What conditions does trial NCT04466150 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome.
What interventions are being tested in trial NCT04466150?
The interventions under investigation include: Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT04466150?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04466150 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
RECRUITING · Phase 4
-
Effects of Ocrevus in Relapsing Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 4
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
RECRUITING · Phase 3
-
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 3
-
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
RECRUITING
-
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
RECRUITING
Explore more on PlainTrial
Relapsing Multiple Sclerosis
All registered trials for this condition
Clinically Isolated Syndrome
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.